CAR-T Therapy Beyond B-Cell Hematological Malignancies
Despite the advances of CAR-T cells in certain hematological malignancies, mostly from B-cell derivations such as non-Hodgkin lymphomas, acute lymphoblastic leukemia and multiple myeloma, a significant portion of other hematological and non-hematological pathologies can benefit from this innovative...
Saved in:
Main Authors: | Martina Canichella, Paolo de Fabritiis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/14/1/41 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity
by: Yaojie Kong, et al.
Published: (2025-01-01) -
Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors
by: Safwaan H. Khan, et al.
Published: (2025-01-01) -
Chimeric cytokine receptor TGF-β RⅡ/IL-21R improves CAR-NK cell function by reversing the immunosuppressive tumor microenvironment of gastric cancer
by: Yaojun Ren, et al.
Published: (2025-02-01) -
CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma
by: Laura M. Moser, et al.
Published: (2025-02-01) -
A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells
by: Zhao Zhang, et al.
Published: (2025-01-01)